The expression of PD-L1 on the surface of tumor cells, detected by immunohistochemistry, is a predictive biomarker to guide the treatment decision for anti-PD-1 or anti-PD-11 antibodies in NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.